Navigation Links
Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
Date:12/1/2008

PT. RICHMOND, Calif., Dec. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to participate at the RBC Capital Markets 2008 Healthcare Conference in New York City on a panel entitled "Delivering Novel Drug Solutions: The Future of Drug Delivery." This presentation is scheduled to take place on Thursday, December 11, 2008 at 1:30 PM Eastern Time.

An audio webcast of the presentation will be available at http://www.transcept.com. The replay of the presentation will be available for 30 days.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration.

For further information, please visit the company's website at: http://www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.

     Contacts:

     Transcept Pharmaceuticals, Inc.       The Ruth Group
     Michael Gill                          Investors / Media
     Director of Communications            Stephanie Carrington / Jason Rando
     (510) 215-3575                        (646) 536-7017 / 7025
     mgill@transcept.com                   scarrington@theruthgroup.com
                                           jrando@theruthgroup.com

'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
2. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
3. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
4. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
5. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
6. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
9. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
10. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... , ... The Global Wellness Summit (GWS), an annual conference for ... wellness, travel, spa and beauty in Europe. The organization asked its partner experts in ... and researchers - to forecast where wellness is headed in Europe. Predictions range from ...
(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the ... tool and as an orthogonal tool for RNAi hit validation. A key reason may ... guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , ...
(Date:5/31/2016)... ... , ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree ... 1986, where he graduated in the top ten percentile of his class. Dr. Ditta ... He has been a member in good standing for thirty years in the American ...
(Date:5/30/2016)... ... May 30, 2016 , ... As the CDC relaxes its stance on traditional ... to keep their households lice free. , According to a May 26 article ... keep kids in the classroom despite the fact that they may be harboring an ...
(Date:5/29/2016)... ... ... Whole Health Supply is happy to announce the favorable reception of its ... new style of nail clipper has a wider jaw opening that is useful for ... actual handle is 2.5mm thick to accommodate the cutting force. This is the maximum ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 ... H1 2016" market research report with comprehensive information ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/27/2016)... 2016 Hutchison China MediTech ... on the highly lucrative global oncology and immunology ... potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) ... strategic partners. HCM,s profitable Chinese healthcare business continues ... expect progress of the mid-to-late-stage pipeline during 2016-17 ...
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
Breaking Medicine Technology: